These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35266569)

  • 21. Safety profile of guselkumab in treatment of patients with psoriasis and coexisting hepatitis B or C: A multicenter prospective cohort study.
    Huang YH; Yen JS; Li SH; Chiu HY
    J Am Acad Dermatol; 2024 May; 90(5):1083-1086. PubMed ID: 38307145
    [No Abstract]   [Full Text] [Related]  

  • 22. Multirefractory bullous pemphigoid, psoriasis and psoriatic arthritis successfully treated with guselkumab.
    Rodríguez-Cuadrado FJ; Roustan-Gullón G; Suárez-Massa D; Hospital-Gil M
    An Bras Dermatol; 2024; 99(5):783-785. PubMed ID: 38876967
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
    McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Chakravarty SD; Xu XL; Subramanian RA; Agarwal P; Sheng S; Jiang Y; Zhou B; Zhuang Y; van der Heijde D; Mease PJ
    Arthritis Rheumatol; 2021 Apr; 73(4):604-616. PubMed ID: 33043600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
    Mease PJ; Gladman DD; Deodhar A; McGonagle DG; Nash P; Boehncke WH; Gottlieb A; Xu XL; Xu S; Hsia EC; Karyekar CS; Helliwell PS
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of guselkumab on three cases of SSc accompanying psoriasis.
    Fukasawa T; Yoshizaki-Ogawa A; Yoshizaki A; Sato S
    Rheumatology (Oxford); 2024 Jan; 63(1):e6-e8. PubMed ID: 37310917
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient.
    Lindsey SF; Weiss J; Lee ES; Romanelli P
    J Drugs Dermatol; 2014 Jul; 13(7):869-71. PubMed ID: 25007373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
    Paul C; van de Kerkhof P; Puig L; Unnebrink K; Goldblum O; Thaçi D
    Eur J Dermatol; 2012; 22(6):762-9. PubMed ID: 23178916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials.
    Sweet K; Song Q; Loza MJ; McInnes IB; Ma K; Leander K; Lakshminarayanan V; Franks C; Cooper P; Siebert S
    RMD Open; 2021 May; 7(2):. PubMed ID: 34011674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of ixekizumab in an HIV-positive patient with psoriatic arthritis.
    Qian F; Yan Y; Huang J; Xu W; Zhu Y; Liu J; Wu X; Chen F
    Int J STD AIDS; 2022 Apr; 33(5):519-521. PubMed ID: 35220812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secukinumab retreatment associated psoriasis flare with pustules.
    El-Komy M; Amer M; Mostafa A; ElKalioby M
    J Dermatolog Treat; 2022 Mar; 33(2):1107-1110. PubMed ID: 32538223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis.
    Cai L; Zhang JZ; Zheng M; Zhang SF; Patekar M
    Chin Med J (Engl); 2021 Sep; 134(21):2629-2631. PubMed ID: 34748527
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug survival of brodalumab is greater in patients with psoriasis and psoriatic arthritis in a real-world setting.
    Gkanti V; Dalamaga M; Papadavid E
    Int J Dermatol; 2023 Jan; 62(1):e31-e34. PubMed ID: 36087047
    [No Abstract]   [Full Text] [Related]  

  • 34. Consideration of confounders, accuracy of diagnosis, and disease severity in assessing the risk of inflammatory bowel disease in patients with psoriasis and psoriatic arthritis/ankylosing spondylitis beginning interleukin-7 inhibitor treatment: comment on the article by Penso et al.
    Yang CR; Ker A; Kao PE; Wei JC
    Arthritis Rheumatol; 2022 Mar; 74(3):546-547. PubMed ID: 34463055
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic arthritis: a systematic review.
    Boehncke WH; Alvarez Martinez D; Solomon JA; Gottlieb AB
    J Rheumatol; 2014 Nov; 41(11):2301-5. PubMed ID: 25362715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ustekinumab for resistant psoriatic arthritis.
    Wallis DE; Waldron NM; Korendowych E
    J Rheumatol; 2013 Feb; 40(2):207. PubMed ID: 23378500
    [No Abstract]   [Full Text] [Related]  

  • 37. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis.
    Bongiorno MR; Pistone G; Doukaki S; Aricò M
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S15-20. PubMed ID: 18837728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
    Coates LC; Gossec L; Theander E; Bergmans P; Neuhold M; Karyekar CS; Shawi M; Noël W; Schett G; McInnes IB
    Ann Rheum Dis; 2022 Mar; 81(3):359-369. PubMed ID: 34819273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guselkumab: widened action in psoriatic disease.
    Arnone M; Carvalho AVE; Fabricio LZ; Romiti R
    Clinics (Sao Paulo); 2021; 76():e2629. PubMed ID: 33978074
    [No Abstract]   [Full Text] [Related]  

  • 40. Psoriasis and psoriatic arthritis in a patient with HIV: response to mycophenolate mofetil treatment.
    Forman SB; Higginson R; Garrett AB
    J Drugs Dermatol; 2008 Oct; 7(10):972-3. PubMed ID: 19112763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.